Specific protection against breast cancers by cyclin D1 ablation

By Qunyan Yu, Y. Geng, P. Sicinski. Nature, 2001

998 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/68e800b7aaad25e0f6ef9a9fb36b1b6cb4013438

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. G. Shapiro
2. E. Musgrove
3. J. M. Roberts
4. C. Sherr

In Molecular Biology

1. G. Shapiro
2. M. Moasser
3. F. McCormick
4. J. Baselga
5. J. M. Roberts
6. N. Turner
7. C. Sherr
8. J. Campisi

In Oncology

1. G. Shapiro
2. M. Moasser
3. E. Musgrove
4. F. McCormick
5. D. Bar-Sagi
6. Y. Pylayeva-Gupta
7. J. Baselga
8. J. M. Roberts

Citations in the corpus

• Cyclin D as a therapeutic target in cancer (2011, background): “Cells lacking all three D-type cyclins are resistant to transformation by various oncogenes in vitro , and mice lacking cyclin D1 are resistant to the effects of some, although not all, mammary oncogene”
• Living with or without cyclins and cyclin-dependent kinases. (2004, background): “Similarly, cyclin D1 inactivation confers resistance to breast cancers induced by oncogenic Neu or Ras transgenes targeted to the mammary gland (Yu et al. 2001) and to intestinal tumors resulting from Apc loss and constitutive -catenin signaling (Hulit et al.”
• PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro (2009, background): “In addition, a pivotal role for cyclin D1 function in HER2-mediated transformation has been described using transgenic mouse models [43].”
• Identification of a Structural Determinant Necessary for the Localization and Function of Estrogen Receptor α at the Plasma Membrane (2003, background): “It has also been recently reported that specifically cyclin D1 is essential to the development of rodent breast cancer, resulting from Ras or Neu oncogene signaling (51).”
• The RB and p53 pathways in cancer. (2002, background): “Moreover, whereas mice overexpressing Her2/Neu or oncogenic Ras transgenes targeted to mammary epithelium rapidly develop breast cancer, they fail to do so in a cyclin D1 null background, indicating that D1 function is essential for tumorigenesis and that other D-type cyclins in breast tissue cannot”
• NF-kB in development and progression of human cancer (2005, background): “NF-kB-induced cyclin D1 expression appears to be a key element in mammary gland development and breast carcinogenesis [73].”